Table 2.

Proportions of participants with baseline BMD < −2.5 SD who achieved BMD ≥ −2.5 SD

Measurement site	TPTD-ALN group			ALN group			P
	Frequency	Proportion	N	Frequency	Proportion	N
L2-4 BMD
24 weeks	5	9.1%	55	14	13.6%	103	0.46
48 weeks	8	14.8%	54	19	18.3%	104	0.66
72 weeks*	6	13.6%	44	12	15.6%	77	1.00
120 weeks*	9	20.5%	44	16	22.2%	72	1.00
Total hip BMD
24 weeks	6	13.0%	46	3	4.1%	73	0.09
48 weeks	7	15.6%	45	6	8.1%	74	0.24
72 weeks	7	15.2%	46	7	9.6%	73	0.39
120 weeks	9	23.1%	39	7	11.7%	60	0.17
Femoral neck BMD
24 weeks	4	4.2%	95	7	5.3%	131	0.76
48 weeks	3	3.2%	94	8	6.0%	134	0.53
72 weeks	5	5.3%	95	9	7.1%	126	0.78
120 weeks	5	5.9%	85	8	7.3%	109	0.78

BMD bone mineral density; SD standard deviation; TPTD teriparatide; ALN alendronate. *Cases of vertebral fracture were excluded